Boing Boing on MSN1h
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.
Hosted on MSN21h
FDA approves Spravato, nasal spray derived from KetamineThe FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback